Marker Therapeutics (MRKR) has released an update.
Marker Therapeutics is making strides in its clinical and financial fronts with significant progress in its Phase 1 APOLLO study for lymphoma and a financial boost from two NIH grants. As they gear up to release preliminary data, the company remains focused on advancing its T cell-based therapies for challenging cancers.
For further insights into MRKR stock, check out TipRanks’ Stock Analysis page.
